OpGen Subsidiary Curetis and Leader Life Sciences Enter into Unyvero Distribution Partnership for U.A.E. and Qatar
June 09 2022 - 7:30AM
OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company
harnessing the power of molecular diagnostics and bioinformatics to
help combat infectious disease, announced today that its subsidiary
Curetis GmbH has entered into a distribution agreement with Leader
Life Sciences via their trading company Leader Medical Supplies
Trading LLC, part of the Leader Healthcare Group, for distribution
of Unyvero systems in the United Arab Emirates and Qatar. Leader
Healthcare Group is one of the Middle East region’s leading
distributors and has a presence in markets such as Saudi Arabia,
Oman, and Egypt.
Under the distribution agreement, Leader Life
Sciences has the exclusive rights to commercialize the Curetis
Unyvero A50 instrument system and its full suite of Unyvero
infectious disease diagnostic application cartridges in U.A.E. and
Qatar. The distribution agreement has an initial term of three
years and can be extended in one-year increments. In return, Leader
Life Sciences has committed to significant minimum purchases of
Unyvero instruments and application cartridges during the initial
three-year term, amounting to a total of at least 8 Unyvero systems
plus significant numbers of Unyvero cartridges for a total deal
value during its initial term of approximately $1 million in
transfer-price based revenue to OpGen. Leader Life Sciences is
responsible for product registration in its territories and has
committed to significantly invest in the market introduction of the
Unyvero product line in U.A.E. and Qatar.
“With a significant number of hospitalized
patients suffering from healthcare-associated infections in the
Middle East, we believe that a rapid and comprehensive detection of
the pathogens and their antibiotic resistance markers with Unyvero
will help to improve outcomes for patients with severe infections
while supporting the antibiotic stewardship efforts that are high
on the agenda of healthcare providers in the region,” said Oliver
Schacht, CEO of OpGen. “We are very pleased to work with Leader
Life Sciences as a highly committed partner in making Unyvero
widely available in the region. This partnership strengthens our
commercial presence in the Middle East region and is in alignment
with our core commercialization strategy to expand our global
presence as industry leaders in the molecular diagnostics and
bioinformatics space. We anticipate working closely with Leader
Life Sciences and the team over the coming years and anticipate the
opportunity to explore potential expansion into additional
countries in the region in the years ahead.”
"The Curetis-Leader Life Sciences strategic
partnership is a powerful combination. Curetis' understanding in
development of molecular diagnostic products for more than a decade
leading to immense improvement in patient outcomes is uniquely
complementary to how Leader Life Sciences' team works. We believe
this alliance will assist in bringing new revolutions in the
industry," said Sukhdeep Sachdev, the Global CEO of Leader
Healthcare Group. "With operations spread across the region, along
with close-to-client location reach and added capabilities of the
cherry-picked team of Leader Life Sciences' well qualified
individuals in different domains, this collaborative effort will
allow us to drive far more impact for our clients."
About OpGen, Inc.
OpGen, Inc. (Rockville, MD, USA) is a
precision medicine company harnessing the power of molecular
diagnostics and bioinformatics to help combat infectious disease.
Along with our subsidiaries, Curetis GmbH and Ares
Genetics GmbH, we are developing and commercializing molecular
microbiology solutions helping to guide clinicians with more rapid
and actionable information about life threatening infections to
improve patient outcomes, and decrease the spread of infections
caused by multidrug-resistant microorganisms, or MDROs. OpGen’s
product portfolio includes Unyvero®, Acuitas® AMR Gene
Panel and the ARES Technology Platform including
ARESdb®, using NGS technology and AI-powered bioinformatics
solutions for antibiotic response prediction.
For more information, please visit
www.opgen.com.
Forward-Looking Statements
This press release includes statements regarding
the entry into an exclusive distribution agreement with Leader Life
Sciences. These statements and other statements regarding OpGen’s
future plans and goals constitute "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 and are intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. Such statements
are subject to risks and uncertainties that are often difficult to
predict, are beyond our control, and which may cause results to
differ materially from expectations. Factors that could cause our
results to differ materially from those described include, but are
not limited to, the success of our commercialization efforts, our
ability to successfully, timely and cost-effectively develop, seek
and obtain regulatory clearance for and commercialize our product
and services offerings, the rate of adoption of our products and
services by hospitals and other healthcare providers, the fact that
we may not effectively use proceeds from recent financings, the
continued realization of expected benefits of our business
combination transaction with Curetis GmbH, the continued
impact of COVID-19 on the Company’s operations, financial results,
and commercialization efforts as well as on capital markets and
general economic conditions, our ability to satisfy debt
obligations under our loan with the European Investment Bank,
the effect of the military action
in Russia and Ukraine on our distributors,
collaborators and service providers, our liquidity and working
capital requirements, the effect on our business of existing and
new regulatory requirements, and other economic and competitive
factors. For a discussion of the most significant risks and
uncertainties associated with OpGen's business, please
review our filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which are based on our expectations as
of the date of this press release and speak only as of the date of
this press release. We undertake no obligation to publicly update
or revise any forward-looking statement, whether as a result of new
information, future events or otherwise.
OpGen:Oliver SchachtPresident and
CEOInvestorRelations@opgen.com
OpGen Press Contact:Matthew Bretzius FischTank
Marketing and PR matt@fischtankpr.com
OpGen Investor Contact:Alyssa FactorEdison
Groupafactor@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2023 to Jul 2024